Allogeneic Plasmacytoid Dendritic Cells, Loaded With Seven Lung Tumor Antigen-Derived Peptides, Irradiated

This article discusses the clinical trials of PDC*lung01, an innovative cancer vaccine designed to treat non-small cell lung cancer (NSCLC). PDC*lung01 is an advanced therapy investigational medicinal product containing allogeneic plasmacytoid dendritic cells loaded with seven lung tumor antigen-derived peptides. The trials aim to assess the safety, tolerability, immunogenicity, and preliminary clinical activity of PDC*lung01 when used alone or in combination with other treatments for NSCLC patients.

What is PDC*lung01?
How Does It Work?
What Condition Does It Treat?
Current Research
Who Might Be Eligible?
Potential Benefits and Risks

What is PDC*lung01?

PDC*lung01 is a new type of cancer vaccine being studied for the treatment of non-small cell lung cancer (NSCLC). It’s classified as an Advanced Therapy Investigational Medicinal Product (ATIMP), which means it’s a cutting-edge treatment that uses biological materials^[1].

The active substance in PDC*lung01 is described as “allogeneic plasmacytoid dendritic cells, loaded with seven lung tumor antigen-derived peptides, irradiated”. This complex name tells us several important things about the vaccine^[1]:

Allogeneic: The cells come from a donor, not the patient themselves.
Plasmacytoid dendritic cells: These are a type of immune cell that helps stimulate the immune system.
Loaded with seven lung tumor antigen-derived peptides: The cells carry pieces of proteins found on lung cancer cells.
Irradiated: The cells have been treated with radiation, likely to prevent them from multiplying uncontrollably in the patient’s body.

How Does It Work?

PDC*lung01 is designed to stimulate the patient’s immune system to fight against lung cancer cells. Here’s a simplified explanation of how it might work^[1]:

The vaccine contains dendritic cells, which are important for activating other immune cells.
These dendritic cells are loaded with pieces of proteins (peptides) that are typically found on lung cancer cells.
When injected into the patient, these cells present the cancer-associated peptides to the patient’s immune system.
This presentation trains the immune system to recognize and attack cells that have these cancer-associated proteins.

The goal is to create a targeted immune response against the patient’s lung cancer cells.

What Condition Does It Treat?

PDC*lung01 is being studied for the treatment of non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer, accounting for about 80-85% of all lung cancers. It’s a serious condition that often has a poor prognosis, especially when diagnosed at later stages^[1].

Current Research

PDC*lung01 is currently being studied in a Phase I/II clinical trial. This study aims to assess several aspects of the vaccine^[1]:

Safety and tolerability
How well it stimulates the immune system (immunogenicity)
Preliminary signs of effectiveness against the cancer

The study is testing PDC*lung01 in different scenarios^[1]:

As a single treatment
In combination with a chemotherapy drug called pemetrexed
In combination with an immunotherapy drug (anti-PD-1 therapy, likely pembrolizumab)

Who Might Be Eligible?

The current study has specific criteria for who can participate. Some key points include^[1]:

Adults (18 years or older) with confirmed NSCLC
Patients must have a specific genetic marker (HLA-A*02:01 positive)
Patients with certain stages of NSCLC, depending on which part of the study they’re in
Patients must be in relatively good overall health

There are also several factors that might prevent someone from participating, such as having certain other medical conditions or having received certain other treatments recently^[1].

Potential Benefits and Risks

As PDC*lung01 is still in the research phase, its benefits and risks are not fully known. The current study aims to gather more information about both^[1].

Potential benefits being studied include:

Stimulation of the immune system to fight cancer cells
Possible improvement in cancer control or survival

Potential risks being monitored include:

Side effects from the vaccine itself
Possible interactions with other treatments
Immune-related side effects

It’s important to note that as an experimental treatment, PDC*lung01 may have unknown risks and may not provide any benefit. Patients considering participating in clinical trials should discuss the potential risks and benefits thoroughly with their healthcare providers^[1].

Aspect	Details
Study Type	Open-label, dose-escalation, phase I/II study
Primary Objective	Assess safety and tolerability of PDC*lung01 at two dose levels
Treatment Groups	1. PDClung01 as single agent or with pemetrexed 2. PDClung01 with anti-PD-1 therapy
Eligibility	Adults with NSCLC, HLA-A*02:01 positive, adequate organ function
Primary Endpoint	Occurrence of dose-limiting toxicities related to PDC*lung01
Secondary Endpoints	Safety, immune response, clinical activity (response rates, progression-free survival)
Administration	Injection (intravenous, subcutaneous, or intramuscular)

Aspect

Details

Study Type

Open-label, dose-escalation, phase I/II study

Primary Objective

Assess safety and tolerability of PDC*lung01 at two dose levels

Treatment Groups

1. PDC*lung01 as single agent or with pemetrexed 2. PDC*lung01 with anti-PD-1 therapy

Eligibility

Adults with NSCLC, HLA-A*02:01 positive, adequate organ function

Primary Endpoint

Occurrence of dose-limiting toxicities related to PDC*lung01

Secondary Endpoints

Safety, immune response, clinical activity (response rates, progression-free survival)

Administration

Injection (intravenous, subcutaneous, or intramuscular)

Ongoing Clinical Trials on Allogeneic Plasmacytoid Dendritic Cells, Loaded With Seven Lung Tumor Antigen-Derived Peptides, Irradiated

Glossary

Allogeneic: Cells or tissues that are derived from a different individual of the same species. In this context, it refers to dendritic cells that come from a donor rather than the patient themselves.
Plasmacytoid Dendritic Cells: A type of immune cell that plays a crucial role in detecting and responding to viral infections and can also stimulate other immune cells to fight cancer.
Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that includes several subtypes, such as adenocarcinoma and squamous cell carcinoma. It is the most common form of lung cancer.
Immunogenicity: The ability of a substance to provoke an immune response in the body. In this context, it refers to how well PDC*lung01 can stimulate the immune system to fight cancer cells.
Dose-Limiting Toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dosage or require a dosage reduction.
HLA-A*02:01: A specific type of Human Leukocyte Antigen (HLA) molecule. Patients must be positive for this HLA type to be eligible for the PDC*lung01 trials.
Anti-PD-1 Therapy: A type of immunotherapy that helps the immune system recognize and attack cancer cells by blocking the PD-1 protein on immune cells.
Pemetrexed: A chemotherapy drug used to treat certain types of non-small cell lung cancer, often used in maintenance therapy.
RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
Progression-Free Survival: The length of time during and after treatment that a patient lives with cancer without it worsening.

References

http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-pdclung01-vaccine-with-pemetrexed-or-pembrolizumab-for-patients-with-non-small-cell-lung-cancer/

#1 Clinical Trials Search in Europe